265312-92-3

Basic information

• Product Name: 1-O-allyl-2,3,4-tri-O-(tert-butyldimethylsilyl)-6-O-(4-tolylsulfonyl)-α-D-glucopyranoside
• Synonyms: 1-O-allyl-2,3,4-tri-O-(tert-butyldimethylsilyl)-6-O-(4-tolylsulfonyl)-α-D-glucopyranoside
• CAS NO: 265312-92-3
• Molecular Weight: 717.2
• Mol File: 265312-92-3.mol
• Article Data: 5

Chemical Properties

• CAS DataBase Reference: 1-O-allyl-2,3,4-tri-O-(tert-butyldimethylsilyl)-6-O-(4-tolylsulfonyl)-α-D-glucopyranoside(CAS DataBase Reference)
• NIST Chemistry Reference: 1-O-allyl-2,3,4-tri-O-(tert-butyldimethylsilyl)-6-O-(4-tolylsulfonyl)-α-D-glucopyranoside(265312-92-3)
• EPA Substance Registry System: 1-O-allyl-2,3,4-tri-O-(tert-butyldimethylsilyl)-6-O-(4-tolylsulfonyl)-α-D-glucopyranoside(265312-92-3)

Safety Data

• Hazardous Substances Data: 265312-92-3(Hazardous Substances Data)

Upstream product

• 108-48-5 2,6-dimethylpyridine 
• 69739-34-0 t-butyldimethylsiyl triflate 
• 267900-42-5 1-O-(2-propenyl)-6-O-(4-tolylsulfonyl)-α-D-glucose 
• 93382-48-0 allyl 4,6-O-benzylidene-α-D-glucopyranoside 
• 2280-44-6 D-Glucose 
• 98-59-9 p-toluenesulfonyl chloride 
• 7464-56-4 1-O-allyl-α-D-glucopyranoside 

Downstream Products

• 1234307-20-0 C₅₄H₉₉IO₁₀SSi₃ 
• 1234307-22-2 C₅₂H₉₆IO₁₂SSi₃^(1-)*Na⁽¹⁺⁾ 
• 1234307-23-3 C₃₄H₅₄IO₁₂S^(1-)*Na⁽¹⁺⁾ 
• 1234307-24-4 C₅₄H₉₇I₃O₁₀SSi₃ 
• 1234307-25-5 C₅₂H₉₄I₃O₁₂SSi₃^(1-)*Na⁽¹⁺⁾ 
• 1234307-26-6 C₃₄H₅₂I₃O₁₂S^(1-)*Na⁽¹⁺⁾ 

Relevant articles and documents

COMPOUND RETAINED IN TUMOR

A novel compound which specifically resides in a tumor, a method for allowing it to reside in a tumor, and a method for detecting, diagnosing, and treating tumor with use thereof are provided. The present invention relates to a compound represented by chemical formula (I) wherein R is an anionic group binding to hydrogen, R1 is OH, OCOH, OCO(CH2)hCH3, or an acting group, h being an integer of 0 or more, R2 is H, OH, OCOH, OCO(CH2)iCH3, or an acting group, i being an integer of 0 or more, R3 is OH, SO3H, or an acting group, R4 is OH, SO3H, or an acting group, and R5 is OH, SO3H, or an acting group, at least one of R1, R2, R3, R4, and R5 containing an acting group, or pharmaceutically acceptable salts thereof.

Medicament containing a sulfopyranosylacylglycerol derivative

A medicament containing at least one compound selected from the group consisting of compounds represented by General formula (1): wherein R101 represents an acyl residue of an unsaturated higher fatty acid, and R102 represents a hydr

Synthesis of sulfoquinovosylacylglycerols, inhibitors of eukaryotic DNA polymerase α and β

Sulfoquinovosyldiacylglycerols (SQDGs) and sulfoquinovosylmonoacylglycerols (SQMGs), bearing diverse fatty acids, were synthesized from d-glucose, and were examined for enzymatic inhibitions of DNA polymerase α and β. These results indicated that the carbon numbers of the fatty acids were highly related to the activities, at least in vitro, of eukaryotic DNA polymerase inhibition.